Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
151.7 SEK | -0.46% | +3.41% | -16.88% |
Mar. 12 | Surgical Science Sweden to Step Down; Search for Successor Starts | MT |
Mar. 12 | Gisli Hennermark Intends to Leave as CEO of Surgical Science Sweden AB | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With an expected P/E ratio at 39.6 and 35.79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.88% | 724M | - | ||
+20.35% | 37.38B | C | ||
+8.26% | 7.07B | C- | ||
+14.92% | 3.74B | B- | ||
-0.73% | 3.73B | C- | ||
-22.32% | 1.34B | B | ||
-28.33% | 1.25B | - | ||
-30.38% | 974M | - | ||
-8.04% | 822M | C | ||
-20.75% | 540M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Surgical Science Sweden AB - Nasdaq Stockholm
- Ratings Surgical Science Sweden AB